Braun Launches the World’s First Smart At-Home IPL System That Learns and Adapts to Your Skin and Hair to Give You 1 Year of Smooth Skin*
8.2.2024 15:00:00 CET | Business Wire | Press Release
From its home of IPL at its world-class innovation facility in Kronberg, Germany, the pioneering German electronics brand, Braun, today introduces the Braun Skin i·expert - the only fully connected IPL system that learns, adapts, and provides personalised feedback in real time.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240131964639/en/
Braun Skin i·expert. Fully connected IPL system. (Photo: Business Wire)
The revolutionary new Skin i·expert is Braun’s fastest way to 1 year of smooth skin*, all in the comfort of your own home.
A smart system that automatically adapts the energy to your skin tone providing you with an active real-time personalised treatment guidance per body area – Braun puts the power in your hands, offering a more comfortable hair removal experience with the new Braun Skin i·expert.
All IPL devices within the Braun portfolio have been designed to offer fast, safe, almost painless hair removal and undergo countless R&D tests and scientific research to deliver the desired results you want and need.
Braun IPL devices are assessed by independent dermatologists and certified by Skin Health Alliance's high skin safety standards
- Smart Coverage Feedback and Smart Head Recognition enables you to achieve your best results by guiding you in real-time to avoid missing any treatment areas.
- The only one** with automatic flash power adaptation to your unique skin tones and a Skin Check to achieve your best results, in full safety. Followed by personalized tips on how you can improve your next session.
- No need to worry about missing an appointment thanks to its built in Personal Progress Tracker and Smart Calendar that enables you to stay on track by automatically adapting the sessions schedule by showing you how many treatments you still have left. Take control of your hair removal journey with ease and at a fraction of the cost of going to a salon.
Braun’s new IPL smart device is a step change to your hair removal routine, it gives the power to you to get long-lasting smooth skin safely, easily from the comfort of your home.
Ahmed Aboulenein, Global Vice President at Braun, said: “At Braun's Kronberg Innovation Center, our team are committed to designing durable and user-centered innovations that leverage cutting-edge technologies. Our aim is to delight consumers and address their Grooming everyday problems effectively. By gathering insights and data from consumers worldwide, Braun has identified a need for solutions that enable users to achieve safe and long-lasting smooth skin at home. This valuable information has informed our latest breakthrough IPL innovation. Our ultimate objective is to empower consumers, allowing them to achieve safe, long-lasting smooth skin comfortably from the convenience of their own homes. What sets the new Braun Skin i-expert apart is its seamless integration of smart technology, connecting the IPL device with a dedicated mobile app. This comprehensive system learns and adapts to the user's specific skin and hair needs, guiding them step by step through the entire treatment process. It provides real-time personalized feedback, making it remarkably user-friendly for both experienced IPL users and beginners.”
Dr. Christine Dierickx, MD, a leading cosmetic dermatologist and Director of Skinperium Laser and Cosmetic Dermatology Clinic in Luxembourg, said: “Hair removal is one of the top three reasons why patients visit a dermatologist. Many consumers opt also for salons as they believe at-home devices are complicated and do not deliver the desired results. The Braun Skin i·expert is a unique device that has been developed after years of research. It features an intuitive smart system that makes hair removal extremely simple for consumers. The device learns use after use to provide a personalized experience tailored just to you. Additionally, the automatic flash power adapts to your unique skin tones to ensure you achieve the best results, in full safety. The new Braun Skin i·expert is set to revolutionize the way we remove hair at home.”
*Following the regimen. Individual results may vary.
**Shared technology with Cyden
***Further reading: Hattersley AM, Kiernan M, Goldberg D, Dierickx C, Sliney DH, Haedersdal M, et al. Assessment of adverse events for a home‐use intense pulsed light hair removal device using postmarketing surveillance. Lasers Surg Med. 2023;1–9. https://doi.org/10.1002/lsm.23650
Notes to editors
About Braun
Braun, a subsidiary of Procter & Gamble founded in Germany in 1921, develops and manufactures a wide variety of small domestic appliances that marry technical innovation, reliable quality and distinctive design. These range from electric shavers and beauty products to household appliances, watches and speakers. Braun products enjoy worldwide distribution. Please visit www.braun.com for the latest news and in-depth information about the Braun brand.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240131964639/en/
Contact information
Alexandra Smart
alexandra.smart@pgone.co.uk
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press Release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press Release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press Release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press Release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press Release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom